Авастин в клинической химиотерапии злокачественных опухолей

Читать PDF

Аннотация

Авастин (бевацизумаб) – гуманизированное моноклональное антитело, обладающее выраженной антиангиогенной активностью, прицельно блокирующее сосудистый эндотелиальный фактор роста VEGF и предотвращающее его связывание с рецепторами. Хронологически Авастин является одним из первых (вторым после трастузумаба) таргетных препаратов, разрешенных для применения в клинической практике. Также он является единственным таргетным препаратом, применяемым при основных злокачественных солидных опухолях: метастатическом колоректальном раке, местно-рецидивирующем или метастатическом раке молочной железы, местно-распространенном, метастатическом или рецидивирующем неплоскоклеточном немелкоклеточном раке легкого, распространенном и/или метастатическом почечно-клеточном раке, глиобластоме (глиома 4-й степени злокачественности по классификации Всемирной организации здравоохранения) и эпителиальном раке яичника, маточной трубы и первичном раке брюшины. Таким образом, в результате многочисленных исследований Авастина в онкологии, проведенных в течение более 10 лет, Авастин можно охарактеризовать сегодня двумя словами: первый и лучший, поскольку ни один таргетный препарат не нашел столь широкого клинического применения и показаний в практической онкологии, и, более того, практически ни одно клиническое исследование Авастина не было безуспешным. Следует сказать также, что большой клинический опыт показывает относительную безопасность препарата в различных подгруппах и популяциях больных.

Ключевые слова: Авастин, ангиогенез, эндотелиальный фактор роста сосудов, таргетные препараты, колоректальный рак, рак молочной железы, немелкоклеточный рак легкого, почечно-клеточный рак, глиобластома, рак яичников, рак фаллопиевой трубы, первичный рак брюшины.

________________________________________________

Avastin (bevacizumab) is a humanized monoclonal antibody with evident antiangiogenic activity, which blocks vessel endothelial growth factor (VEGF) and prevent its binding with receptors. Chronologically Avastin was among the first (second after trastuzumab) targeted agents approved for clinical practice. Also it is the only targeted agent used in the main malignant solid tumor types: metastatic colorectal cancer, locally recurrent or metastatic breast cancer, metastatic or recurrent nonsquamous non-small cell lung cancer, advanced and/or metastatic renal cell cancer, glioblastoma (stage IV glioma according to WHO classification) and epithelial ovarian, fallopian tube, or primary peritoneal cancer. Therefore Avastin can be defined today as the first and the best, because not one targeted agent has so wide clinical use and indications in practical oncology and moreover practically there were no ineffective clinical trials with Avastin. Also it is necessary to mention that large clinical experience with Avastin demonstrates comparative safety of the agent in different patient’s subgroups and populations.

Key words: Avastin, angiogenesis, vessel endothelial growth factor, targeted agents, colorectal cancer, breast cancer, non-small cell lung cancer, renal cell cancer, glioblastoma, ovarian cancer, fallopian tube cancer, primary peritoneal cancer.

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Hurwitz H, Fehrenbacher L, Cartwright T et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med 2004; 350 (23): 2335–42.
2. Saltz LB, Clarke S, Dнaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013–9.
3. Guan ZZ, Xu JM, Luo RC et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: A randomized phase III ARTIST trial. Chin J Cancer 2011; 30: 682–9.
4. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60–5.
5. Kabbinavar FF, Schulz J, McCleod M et al. Addition оf bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697–705.
6. Tebbutt NC, Wilson K, Gebski VJ et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191–8.
7. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539–44.
8. Hurwitz H, Tebbutt NC, Kabbinavar F et al. Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials. The Oncologist 2013; 18: 1004–12.
9. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539–44.
10. Saltz LB, Clarke S, Dнaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013–9.
11. Cassidy J, Saltz LB, Giantonio BJ et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010; 136: 737–43.
12. Welch S, Spithoff K, Rumble RB et al. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: A systematic review. Ann Oncol 2010; 21: 1152–62.
13. Price TJ, Zannino D, Wilson K et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab, and mitomycin C. Ann Oncol 2012; 23: 1531–6.
14. Bendell JC, Bekaii-Saab TS, Cohn AL et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: Results from ARIES, a bevacizumab observational study. The Oncologist 2012; 17: 1486–95.
15. Arnold D, Kindler M, Petersen V et al. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: First results from a large community-based observational cohort study in Germany. Presented at: the 2010 Gastrointestinal Symposium; January 22–24, 2010; Orlando, Florida, USA.
16. Peeters M, Siena S, Tabernero J. Survival outcomes in the PRIME study for patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC), by baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS). J Clin Oncol 2014; 32 (Suppl.): 5, Abstract 3557.
17. Rivera F. Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC). ASCO Annual 2014; Abstract 3629.
18. Ning Y. Genetic variants of TCF7L2 and AXIN2 predict gender and tumor location-dependent clinical outcome in FIRE-3 trial: A validation study. ASCO Annual Meeting 2014; Abstract 3602.
19. Martin P, Jung S-H, Johnson J. CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. J Clin Oncol 2014; 32 (Suppl.): 5, Abstract 8521.
20. Gray R, Bhattacharya S, Bowden C et al. Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer. J Clin Oncol 2009; 27 (30): 4966–72.
21. Miles D, Chan A, Romieu G et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008; 26 (Suppl.): 43.
22. Robert NJ, Die´ras V, Glaspy J. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer. J Clin Oncol 2011; 29 (10): 1252–60.
23. O’Shaughnessy J, Dieras V, Glaspy J et al. Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC). Cancer Res 2009; 69: 512, Abstract 207.
24. Miles DW, Diéras V, Cortés J et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2014; 24 (11): 1–8.
25. Sandler A, Yi J, Dahlberg S et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010; 5: 1416–23.
26. Dansin E et al. ESMO 2010.
27. Nadler E, Yu E, Ravelo A. Bevacizumab Treatment to Progression After Chemotherapy: Outcomes from a U.S. Community Practice Network. The Oncologist 2011; 16 (4): 486–96.
28. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473–83.
29. Perren T, Swart A-M, Pfisterer J et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer N Engl J Med 2011; 365: 2484–96.
30. Aghajanian C, Blank SV, Goff BA et al: OCEANS: A randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinumsensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039–45.
31. Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. J Clin Oncol 2013; 54.
32. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007; 25: 4127–36.
33. Nghiemphu PL, Liu W, Lee Y et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009; 72: 1217–22.
34. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70: 779–87.
35. Pope WB, Lai A, Nghiemphu P et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006; 66: 1258–60.
36. Stark VV. Bevacizumab (Avastin) and CPT-11 (Camptosar) in the treatment of relapsed malignant glioma (abstract). Neurooncology 2005;7: 369.
37. Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588–93.
38. Wagner SA, Desjardins A, Reardon DA, et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas (abstract). J Clin Oncol 2008; 26: 2021.
39. Vredenburgh JJ, Desjardins A, Herndon 2nd JE et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13: 1253–9.
40. Vredenburgh JJ, Desjardins A, Herndon 2nd JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722–9.
41. Cloughesy TF, Prados MD, Mikkelsen T et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) (abstract). J Clin Oncol 2008; 26: 2010b.
42. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab and irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740–5.

Авторы

В.А.Горбунова

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

________________________________________________

V.A.Gorbunova

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.